Cynata Therapeutics Ltd Sustainability Reports
Cynata Therapeutics Limited develops and commercializes scalable biopharmaceutical products based on its proprietary Cymerus mesenchymal stem cell technology. Its therapeutic pipeline primarily focuses on treating conditions such as graft-versus-host disease, diabetic foot ulcers, and osteoarthritis.
Sector: Manufacturing
Country: Australia
Exchange: Australian Securities Exchange
LEI: 529900JYC1BK5YKVJR73
FIGI: BBG001T09MY0
7 reports from 2016 to 2024
